Pierre Falardeau
Vorsitzender bei Folia Biotech, Inc.
Profil
Pierre Falardeau is currently the Chairman of Folia Biotech, Inc. and a Director at EVAH Corp.
He previously served as the President & Chief Executive Officer of Ecopia BioSciences, Inc., Verlyx Pharma, Inc., and Thallion Pharmaceuticals, Inc. He also held the position of Vice President-Scientific Affairs at Æterna Zentaris, Inc. Dr. Falardeau earned a doctorate degree from Université Laval in 1987.
Aktive Positionen von Pierre Falardeau
Unternehmen | Position | Beginn |
---|---|---|
Folia Biotech, Inc.
Folia Biotech, Inc. Drugstore ChainsRetail Trade FOLIA BIOTECH, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on exploiting its proprietary immuno-therapeutic platform to bring to market efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases. The company was founded by Denis Leclerc in 2006 and is headquartered in Quebec, Canada. | Vorsitzender | 01.01.2014 |
EVAH Corp.
EVAH Corp. Information Technology ServicesTechnology Services EVAH Corp. develops animal health technologies. The Canadian company was founded in 2020 by Michel Fortin and Nicole Blanchard. Michel Fortin has been the CEO since 2020. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Pierre Falardeau
Unternehmen | Position | Ende |
---|---|---|
THALLION PHARMACEUTICALS INC. | Geschäftsführer | 12.06.2009 |
Ecopia BioSciences, Inc.
Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Vorstandsvorsitzender | 01.01.2007 |
AETERNA ZENTARIS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Vorstandsvorsitzender | - |
Ausbildung von Pierre Falardeau
Université Laval | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AETERNA ZENTARIS INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Thallion Pharmaceuticals, Inc.
Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Health Technology |
Ecopia BioSciences, Inc.
Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Health Technology |
Folia Biotech, Inc.
Folia Biotech, Inc. Drugstore ChainsRetail Trade FOLIA BIOTECH, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on exploiting its proprietary immuno-therapeutic platform to bring to market efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases. The company was founded by Denis Leclerc in 2006 and is headquartered in Quebec, Canada. | Retail Trade |
EVAH Corp.
EVAH Corp. Information Technology ServicesTechnology Services EVAH Corp. develops animal health technologies. The Canadian company was founded in 2020 by Michel Fortin and Nicole Blanchard. Michel Fortin has been the CEO since 2020. | Technology Services |